

شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلو

# بسم الله الرحمن الرحيم





MONA MAGHRABY



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلو



شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



MONA MAGHRABY



شبكة المعلومات الجامعية التوثيق الإلكترونى والميكروفيلم

# جامعة عين شمس التوثيق الإلكتروني والميكروفيلم قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY

# Evaluation of Serum Markers of Iron Metabolism in Patients with chronic Liver Disease

### AThesis

Submitted for partial fulfillment of Master degree in Pediatrics

 $\mathfrak{B}$ 

#### **Eman Ali Hassan Senosy**

M.B.B.Ch, Ain Shams University (2012)

Under Supervision of

## Prof. Dr. Zainab Anwar El Qabany

Professor of Pediatrics Faculty of Medicine, Ain Shams University

## Dr. Asmaa Wafeeq Abdel Aziz

Lecturer of Pediatrics
Faculty of Medicine, Ain Shams University

### **Dr. Dina Aly Mohamed**

Assistant Professor of Clinical Pathology Faculty of Medicine, Ain Shams University

Faculty of Medicine Ain Shams University **2021** 



سورة البقرة الآية: ٣١



First and foremost, I feel always indebted to Allah, the Most Beneficent and Merciful who gave me the strength to accomplish this work.

My deepest gratitude to **Prof. Dr. Zainab Anwar El Qabany,** Professor of Pediatrics, Faculty of Medicine, Ain Shams University, for her valuable guidance and expert supervision, in addition to her great deal of support and encouragement. I really have the honor to complete this work under her supervision.

I would like to express my great and deep appreciation and thanks to **Dr. Asmaa Wafeeq Abdel Aziz,** Lecturer of Pediatrics, Faculty of Medicine, Ain Shams University, for her meticulous supervision, and her patience in reviewing and correcting this work. Also, for guiding me throughout this work and for granting me much of her time. I greatly appreciate her efforts.

I Cant' forget to thank with all apppreciation **Dr. Dina Aly Mohamed,** Assistant Professor of Clinical Pathology,

Faculty of Medicine, Ain Shams University, for the efforts and time she has devoted to accomplish this work.

Special thanks to my **Parents**, my **Husband** and all my **Family** members for their continuous encouragement, enduring me and standing by me.

🗷 Eman Ali Hassan Senosy

# **List of Contents**

| Subject                                  | Page No. |
|--|----------|
| List of Abbreviations                    | i        |
| List of Tables                           | iv       |
| List of Figures                          | v        |
| Introduction                             | 1        |
| Aim of the Work                          | 3        |
| Review of Literature                     |          |
| Chronic liver diseases in children       | 4        |
| Iron metabolism                          | 27       |
| Iron metabolism in Chronic Liver Disease | 39       |
| Patients and Methods                     | 52       |
| Results                                  | 58       |
| Discussion                               | 67       |
| Summary                                  | 74       |
| Conclusion and Recommendations           | 77       |
| References                               | 78       |
| Arabic Summary                           |          |

#### **List of Abbreviations**

Abbr. Full-term

**ABCB11** : Adenosine triphosphate binding cassette,

subfamily B, member 11

**ABCB4** : Adenosine triphosphate binding cassette,

subfamily B, member 4

**ABCC2** : ATP-binding cassette, subfamily C, member 2

**AGS** : Alagille Syndrome

**AIH** : Autoimmune Hepatitis

**ALA** : Aminolevulinic acid

**ATP8B1** : Adenosine triphosphatase, type 8B, member 1

**BCS**: Budd-Chiari syndrome

**BMP** : Bone morphogenetic protein

**CF** : Cystic Fibrosis

**CFTR** : Cystic fibrosis transmembrane conductance regulator

**CHF** : Congenital hepatic fibrosis

**CLD** : Chronic liver diseases

**CMV** : Cytomegalovirus infection

**CN** : Crigler-Najjar syndrome

**CPK** : Creatinine phsophokinase

**DJS**: Dubin Johnson syndrome

**DMT1** : Divalent metal transporter 1

**DNA** : Deoxyribonucleic acid

**EBV** : Epstein bar virus

**ERCP** : Endoscopic retrograde cholangiopancreatography

**ESR** : Erythrocyte sedimentation rate

**Fe2+** : Divalent ferrous

**Fe3**+ : Trivalent ferric

**FPN**: Ferroprotein

**Fpn1** : Ferroportin-1

**GGT** : Gamma glutamyl transpeptidases

**GSD** : Glycogen Storage Diseases

**HAMP** : Hepcidin Antimicrobial Peptide

**HBV**: Hepatitis B Virus

**HCV**: Hepatitis C Virus

**HHC** : Hereditary hemochromatosis

**IBS** : Inspisated Bile Syndrome

**IgG**: Immunoglobulin G

**IL-6** : Interleukin-6

**IQR** : Interquartile range

**IREs**: Iron-responsive elements

**IRP**: Iron regulatory proteins

**mRNAs** : Messenger ribonucleic acids

**MRP2** : Multidrug resistance protein 2

**NPC**: Niemann–Pick disease type C

NTBI : Non-transferrin bound iron

**ORCH**: Toxoplasma, rubella, cytomegalovirus, herpes simplex

**PBC**: Primary biliary cirrhosis

**PC** : Personal computer

**PCR** : Polymerase chain reaction

**PFIC** : Progressive familial intrahepatic cholestases

**PKD** : Polycystic kidney disease

**PSC**: Primary sclerosing cholangitis

**RES** : Reteiclo endothelial system

**SD** : Standard deviation

**SNHL** : Sensorineural hearing loss

**SPSS** : Statistical package for social science

**STAT** : Signal transducers and activators of transcription

**TBI** : Transferrin bound iron

**Tf**: Transferrin

**TfR** : Transferrin receptors

**TIBC**: Total iron-binding capacity

**TORCH**: Toxoplasmosis, Rubella, Cytomegalovirus, Herpes

simplex virus

**UGT1A1** : UDP-glucuronosyl transferase 1 family, polypeptide A1

**WD** : Wilson's Disease

# **List of Tables**

| Table No.          | . Title  | Page No. |
|--------------------|--|----------|
| <b>Table (1):</b>  | Causes of chronic liver diseases children  |          |
| <b>Table (2):</b>  | Causes of neonatal and infancholestasis  |          |
| <b>Table (3):</b>  | Investigations of chronic liver disease children                                       |          |
| <b>Table (4):</b>  | Iron chelation therapy   | 51       |
| <b>Table (5):</b>  | Demographic data between control case groups.  |          |
| <b>Table (6):</b>  | Diagnosis category and Child's-P classification among cases group                      | _        |
| <b>Table (7):</b>  | Examination among cases group  | 60       |
| <b>Table (8):</b>  | Lab investigations among cases group   | p 60     |
| <b>Table (9):</b>  | Iron profile between control and c groups.   |          |
| <b>Table (10):</b> | Iron profile in relation to sex ame cases group.                                       |          |
| <b>Table (11):</b> | Iron profile between age catego among cases group.                                     |          |
| <b>Table (12):</b> | Iron profile in relation to chi classification among cases group                       |          |
| <b>Table (13):</b> | Iron profile among cases group correlation to progression in chile Pugh classification | d's-     |

# **List of Figures**

| Figure N    | 6. Title   | Page No.                        |
|-------------|--|---------------------------------|
|             | Distribution of iron in human body.  |                                 |
| Figure (2): | The Transferrin Cycle  | 31                              |
| Figure (3): | The main tissues involved in regulation of systemic iron metabo Duodenal enterocytes are respon for dietary iron absorption                                | lism.<br>sible                  |
| Figure (4): | Iron Transport across the Intes<br>Epithelium  |                                 |
| Figure (5): | The Transferrin Cycle  | 38                              |
| Figure (6): | Hepcidin regulation of FPN prexpression during changes in systimon levels  | emic                            |
| Figure (7): | Regulation of hepcidin by BMP/SM inflammatory and hypoxia/ erythroposignaling in the liver   | oietic                          |
| Figure (8): | Regulation of systemic iron metaboand hepcidin expression.   |                                 |
| Figure (9): | Fenton reaction to produce hydradicals, which can cause membrate and hepatocellular damage and hepatocellular damage carcinoma once they are in cytoplasm. | orane<br>nage,<br>llular<br>the |

#### Introduction

From is essential for most living organisms. In an unbound state, however, it is highly reactive and leads to oxidative stress (*Ganz*, 2013) Thus, iron is coupled to transferrin in serum, whereas it is stored in a ferritin-bound form in tissue (*Ganz*, 2013 & *Drakesmith*, *Prentice*, 2012). Small amounts of ferritin are load. Circulating iron constitutes a small, but highly dynamic iron transit compartment that becomes rapidly altered in disease states (*Ganz*, 2012 &. *Gkouvatsos et al.*, 2012) and increased serum iron load leads to emergence of the highly reactive non-transferrin bound iron (NTBI) (*Brissot et al.*, 2012 & *Koskenkorva-Frank et al.*, 2013).

The liver is a critical controller of iron metabolism as it represents a large iron storage compartment and a major producer of ferritin, transferrin and hepcidin (*Pietrangelo*, 2015 & Meynard et al., 2014). In chronic liver disease, low concentrations of hepcidin, which blocks the absorption of iron from the intestine and the release of iron from macrophages, (Ganz, 2012 & Pietrangelo, 2015) contribute to parenchymal iron overload, whereas increased hepcidin concentrations, as observed during chronic inflammation, lead to the sequestration of iron within macrophages thereby promoting anaemia (*Pietrangelo*, 2015 & Weiss, 2015).

As a negative acute phase protein, transferrin is down regulated during episodes of acute inflammation and in advanced liver disease (Ritchie et al., 1999 & Potter et al., 1985), whereas the acute phase protein ferritin also serves as a surrogate of hepatocellular damage (Bhagat et al., 2000). In recent years, there accumulated a lot of new data, some of them the clinical significance of contradictory, about parameters of iron metabolism as surrogate markers of siderosis and severity of liver disease (Weiss, 2015 & Potter et al., 1985). There remain open questions regarding the clinical significance of serum parameters of iron metabolism and hepcidin in various chronic liver diseases and the role of some genetic factors and environmental factors for organic liver damage during overload syndrome iron (Potter BJ, Chapman RW, Nunes, 1985).

# **Aim of the Work**

- To describe the parameters of iron metabolism in patients with chronic liver disease
- To measure the correlation between serum parameters of iron metabolism and severity of chronic liver disease.